Wednesday, March 14, 2012
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said it achieved strong T-cell immune responses in a Phase I study of Pennvax-B, its product for treating the HIV subtype prevalent in North America and Europe. All 12 HIV-positive patients completed the four-dose vaccination regimen, and there were no adverse events or vaccine-related Grade 3 or Grade 4 adverse events noted. The interim results were presented at the Vaccine World Summit 2012 meeting in Hyderabad, India.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.